Cell-based therapeutics: The next pillar of medicine

Science Translational Medicine

Volumn 5, Issue 179, 2013, Pages

  Fischbach, Michael A ^a   Bluestone, Jeffrey A ^b   Lim, Wendell A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYTOCHROME P450; INSULIN DERIVATIVE; INSULIN RECEPTOR; INSULIN RECEPTOR ANTIBODY; INTERLEUKIN 6 ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; METFORMIN; MONOCLONAL ANTIBODY; ORGANIC ANION TRANSPORTER 1; PHOSPHOTRANSFERASE INHIBITOR; ROSIGLITAZONE; UNCLASSIFIED DRUG;

CELL ENGINEERING; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYTOKINE STORM; DNA POLYMORPHISM; DRUG DISTRIBUTION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; FECAL TRANSPLANTATION; GENE; GENETIC CODE; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE TRANSFORMATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MOLECULAR RECOGNITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OCT1 GENE; ORGANIC CHEMISTRY; PANCREAS ISLET TRANSPLANTATION; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN ENGINEERING; REGENERATIVE MEDICINE; REVIEW; THERAPY; TUMOR CELL DESTRUCTION;

DRUG INDUSTRY; HUMANS; MEDICINE; TISSUE THERAPY;

EID: 84875966999     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005568     Document Type: Review

References (27)

1. C. Mason, D. A. Brindley, E. J. Culme-Seymour, N. L. Davie, Cell therapy industry: Billion dollar global business with unlimited potential. Regen. Med. 6, 265-272 (2011).
2. C. G. Brunstein, J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar, J. E. Wagner, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profi le and detection kinetics. Blood 117, 1061-1070 (2011).
3. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, C. H. June, Chimeric antigen receptor-modifi ed T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
4. N. P. Restifo, M. E. Dudley, S. A. Rosenberg, Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
5. E. van Nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, E. G. Zoetendal, W. M. de Vos, C. E. Visser, E. J. Kuijper, J. F. Bartelsman, J. G. Tijssen, P. Speelman, M. G. Dijkgraaf, J. J. Keller, Duodenal infusion of donor feces for recurrent Clostridium diffi cile. N. Engl. J. Med. 368, 407-415 (2013).
6. E. J. Culme-Seymour, N. L. Davie, D. A. Brindley, S. Edwards- Parton, C. Mason, A decade of cell therapy clinical trials (2000-2010). Regen. Med. 7, 455-462 (2012).
7. M. Kalos, B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, C. H. June, T cells with chimeric antigen receptors have potent antitumor eff ects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
8. W. A. Lim, Designing customized cell signalling circuits. Nat. Rev. Mol. Cell Biol. 11, 393-403 (2010).
9. Y. Shu, S. A. Sheardown, C. Brown, R. P. Owen, S. Zhang, R. A. Castro, A. G. Ianculescu, L. Yue, J. C. Lo, E. G. Burchard, C. M. Brett, K. M. Giacomini, Eff ect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007).
10. S. J. Sharkis, R. J. Jones, C. Civin, Y.-Y. Jang, Pluripotent stem cell-based cancer therapy: Promise and challenges. Sci. Transl. Med. 4, 127ps9 (2012).
11. N. Uchida, K. Chen, M. Dohse, K. D. Hansen, J. Dean, J. R. Buser, A. Riddle, D. J. Beardsley, Y. Wan, X. Gong, T. Nguyen, B. J. Cummings, A. J. Anderson, S. J. Tamaki, A. Tsukamoto, I. L. Weissman, S. G. Matsumoto, L. S. Sherman, C. D. Kroenke, S. A. Back, Human neural stem cells induce functional myelination in mice with severe dysmyelination. Sci. Transl. Med. 4, 155ra136 (2012).
12. D. Scadden, A. Srivastava, Advancing stem cell biology toward stem cell therapeutics. Cell Stem Cell 10, 149-150 (2012).
13. I. Weissman, Stem cell therapies could change medicine... If they get the chance. Cell Stem Cell 10, 663-665 (2012).
14. P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S. J. O'Day, J. A. Sosman, J. M. Kirkwood, A. M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R. J. Lee, K. T. Flaherty, G. A. McArthur, BRIM-3 Study Group, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
15. A. Sandler, R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, R. Lilenbaum, D. H. Johnson, Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
16. K. P. Lemon, G. C. Armitage, D. A. Relman, M. A. Fischbach, Microbiota-targeted therapies: An ecological perspective. Sci. Transl. Med. 4, 137rv5 (2012).
17. J. L. Sonnenburg, M. A. Fischbach, Community health care: Therapeutic opportunities in the human microbiome. Sci. Transl. Med. 3, 78ps12 (2011).
18. E. Holmes, J. Kinross, G. R. Gibson, R. Burcelin, W. Jia, S. Pettersson, J. K. Nicholson, Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl. Med. 4, 137rv6 (2012).
19. E. O. Petrof, G. B. Gloor, S. J. Vanner, S. J. Weese, D. Carter, M. C. Daigneault, E. M. Brown, K. Schroeter, E. Allen-Vercoe, Stool substitute transplant therapy for the eradication of Clostridium diffi cle infection: 'RePOOPulating' the gut. Microbiome 1, 3 (2013).
20. S. Hacein-Bey-Abina, C. von Kalle, M. Schmidt, F. Le Deist, N. Wulff raat, E. McIntyre, I. Radford, J. L. Villeval, C. C. Fraser, M. Cavazzana-Calvo, A. Fischer, A serious adverse event after successful gene therapy for X-linked severe combined immunodefi ciency. N. Engl. J. Med. 348, 255-256 (2003).
21. A. E. Friedland, T. K. Lu, X. Wang, D. Shi, G. Church, J. J. Collins, Synthetic gene networks that count. Science 324, 1199-1202 (2009).
22. A. Di Stasi, S. K. Tey, G. Dotti, Y. Fujita, A. Kennedy-Nasser, C. Martinez, K. Straathof, E. Liu, A. G. Durett, B. Grilley, H. Liu, C. R. Cruz, B. Savoldo, A. P. Gee, J. Schindler, R. A. Krance, H. E. Heslop, D. M. Spencer, C. M. Rooney, M. K. Brenner, Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
23. P. Au, D. A. Hursh, A. Lim, M. C. Moos Jr., S. S. Oh, B. S. Schneider, C. M. Witten, FDA oversight of cell therapy clinical trials. Sci. Transl. Med. 4, 49fs31 (2012).
24. T. Cheng, N. Rodrigues, H. Shen, Y. Yang, D. Dombkowski, M. Sykes, D. T. Scadden, Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287, 1804-1808 (2000).
25. R. H. Schwartz, T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
26. A. Levskaya, O. D. Weiner, W. A. Lim, C. A. Voigt, Spatiotemporal control of cell signalling using a light-switchable protein interaction. Nature 461, 997-1001 (2009).
27. P. Mali, L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville, G. M. Church, RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).